These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16186869)

  • 1. [Are all LH-RH analogues equally effective in prostate cancer?].
    Fosså SD
    Tidsskr Nor Laegeforen; 2005 Sep; 125(18):2493-5. PubMed ID: 16186869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
    Reis LO; Denardi F; Faria EF; Silva ED
    Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J; Davis R; Frankel D; Kold Olesen T
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
    J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Uchijima Y; Saitoh H
    Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 20. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
    Yri OE; Bjoro T; Fossa SD
    Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.